β-Boswellic acid

Name: β-Boswellic acid
Brand: MedChemExpress
SKU: HY-N2513
Rating: 4.5 (1 reviews)

Cat. No.: HY-N2513 Purity: 99.89%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

β-Boswellic acid is isolated from the gum resin of Boswellia serrata with anticancer, antioxidant activity, anti-inflammatory activity and anti-arthritic pain.β-Boswellic acid is an orally active nonreducing-type inhibitor of the 5-lipoxygenase (5-LO) product formation either interacting directly with the 5-LO or blocking its translocation. β-Boswellic acid inhibits the synthesis of DNA, RNA and protein in human leukemia HL-60 cells with IC₅₀ values ranging from 0.6 to 7.1 μM. β-Boswellic acid is promising for research of diabetes, inflammatory and arthritic diseases.

For research use only. We do not sell to patients.

β-Boswellic acid Chemical Structure

CAS No. : 631-69-6

Size	Price	Stock	Quantity
1 mg	USD 70	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 180	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 290	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of β-Boswellic acid:

β-Boswellic acid (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Lipoxygenase Isoform Specific Products:

View All Isoforms

5-LOX 12-LOX 15-LOX

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

5-LO

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	5 μM Compound: 1	Inhibition of microsomal PGES1 isolated from IL-1beta-stimulated human A549 cells preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis Inhibition of microsomal PGES1 isolated from IL-1beta-stimulated human A549 cells preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis	[PMID: 24844534]
HeLa	IC₅₀	35 μM Compound: 1, BA	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21334793]
HL-60	IC₅₀	15 μM Compound: 1, BA	Anticancer activity against human HL60 cells after 48 hrs by MTT assay Anticancer activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 22123322]
HL-60	IC₅₀	24 μM Compound: 1, BA	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 21334793]
Sf21	IC₅₀	> 40 μM Compound: 26	Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis	[PMID: 31774676]

In Vitro

β-Boswellic acid (0-34 μM, 120 min) inhibits DNA, RNA and protein synthesis of HL-60 cells in a dose-dependent manner^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

β-Boswellic acid (1-20 mg/kg, p.o., daily for 21 days) lowers the blood glucose level, reverses Streptozotocin (STZ) (HY-13753)-mediated bodyweight reduction and reduces the levels of TC, TGs, LDL cholesterol and the serum SGPT, SGOT, ALP and serum creatinine in STZ-induced diabetic rats^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	STZ-induced diabetic rats^[4]
Dosage:	1-20 mg/kg
Administration:	p.o., daily for 21 days
Result:	Produced a significant antihyperglycemic effect on the 5th day onward in STZ-induced diabetic rats and significantly lowered the blood glucose level.

Molecular Weight

456.70

Formula

C₃₀H₄₈O₃

CAS No.

631-69-6

Appearance

Solid

Color

White to yellow

SMILES

C[C@]12[C@@](CC=C3[C@]2(CC[C@]4(C)[C@@]3([H])[C@H]([C@H](C)CC4)C)C)([H])[C@@]5([C@@]([C@](C)([C@H](O)CC5)C(O)=O)([H])CC1)C

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (218.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1896 mL	10.9481 mL	21.8962 mL
5 mM	0.4379 mL	2.1896 mL	4.3792 mL
10 mM	0.2190 mL	1.0948 mL	2.1896 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.89%

Select Batch:

Data Sheet (276 KB) SDS (392 KB)

COA (262 KB) HNMR (259 KB) RP-HPLC (241 KB) MS (89 KB)

Handling Instructions (2659 KB)

References

[1]. Safayhi H, et al. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther. 1992 Jun;261(3):1143-6. [Content Brief]

[2]. Shao Y, et al. Inhibitory activity of boswellic acids from Boswellia serrata against human leukemia HL-60 cellsin culture. Planta Med. 1998 May;64(4):328-31 [Content Brief]

[3]. Huang MT, et al. Anti-tumor and anti-carcinogenic activities of triterpenoid, beta-boswellic acid. Biofactors. 2000;13(1-4):225-30. [Content Brief]

[4]. Khan A, et al. Anti-diabetic potential of β-boswellic acid and 11-keto-β-boswellic acid: Mechanistic insights from computational and biochemical approaches. Biomed Pharmacother. 2022 Mar;147:112669. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.1896 mL	10.9481 mL	21.8962 mL	54.7405 mL
	5 mM	0.4379 mL	2.1896 mL	4.3792 mL	10.9481 mL
	10 mM	0.2190 mL	1.0948 mL	2.1896 mL	5.4741 mL
	15 mM	0.1460 mL	0.7299 mL	1.4597 mL	3.6494 mL
	20 mM	0.1095 mL	0.5474 mL	1.0948 mL	2.7370 mL
	25 mM	0.0876 mL	0.4379 mL	0.8758 mL	2.1896 mL
	30 mM	0.0730 mL	0.3649 mL	0.7299 mL	1.8247 mL
	40 mM	0.0547 mL	0.2737 mL	0.5474 mL	1.3685 mL
	50 mM	0.0438 mL	0.2190 mL	0.4379 mL	1.0948 mL
	60 mM	0.0365 mL	0.1825 mL	0.3649 mL	0.9123 mL
	80 mM	0.0274 mL	0.1369 mL	0.2737 mL	0.6843 mL
	100 mM	0.0219 mL	0.1095 mL	0.2190 mL	0.5474 mL